Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC).

PloS one - 1 Jan 2014

Casadei Gardini Andrea, Capelli Laura, Ulivi Paola, Giannini Massimo, Freier Eva, Tamberi Stefano, Scarpi Emanuela, Passardi Alassandro, Zoli Wainer, Ragazzini Angela, Amadori Dino, Frassineti Giovanni Luca

Abstract excerpt

Anti-EGFR therapy appears to be a potential treatment option for squamous cell anal carcinoma (SCAC). KRAS mutation is a rare event in SCAC, indicating the absence of the principal mechanism of resistance to this type of therapy. However, no information is available from the literature regarding the status of BRAF or PIK3CA in this cancer type. We analysed KRAS, BRAF and PIK3CA status in SCAC patients in relation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anus Neoplasms
Share to Axons

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to Fluorouracil

Share to Gamma Rays

Share to Human papillomavirus 16

Share to Mitomycin

Share to Phosphatidylinositol 3-Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 24642661
DOI: 10.1371/journal.pone.0092071
PMCID: PMC3958420

Genes

BRAF
KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC).PMID 24642661Read ↗

No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC).Semantic proximity Read ↗

EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer.Semantic proximity Read ↗

Low mutation percentage of KRAS and BRAF genes in Brazilian anal tumors.Semantic proximity Read ↗

EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?Semantic proximity Read ↗

KRAS and BRAF mutations in anal carcinoma.Semantic proximity Read ↗

Mutational analysis of KRAS and its clinical implications in cervical cancer patients.Semantic proximity Read ↗

Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection.Semantic proximity Read ↗

K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment?Semantic proximity Read ↗

Molecular biology of anal squamous cell carcinoma: implications for future research and clinical intervention.Semantic proximity Read ↗

No evidence of oncogenic KRAS mutations in squamous cell carcinomas of the anogenital tract and head and neck region independent of human papillomavirus and p16(INK4a) status.Semantic proximity Read ↗

KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review.Semantic proximity Read ↗

p16INK4A, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: correlation with outcomes following chemo-radiotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.